Wockhardt has entered into an settlement with Dubai-based Enso Healthcare DMCC and Human Vaccine (HV) LLC, a wholly-owned subsidiary of the Russian Direct Investment Fund, for the manufacture and provide of the Sputnik V and Sputnik Light vaccine in opposition to Covid-19, the pharmaceutical firm stated in a press release on Friday.

Wockhardt will provide as much as 620 million doses of the Sputnik V vaccine and the Sputnik Light vaccine to Enso “subject to requisite approvals”, it stated.

“Subject to requisite approvals and different situations, upon profitable expertise switch from HV to the corporate, the corporate will manufacture and provide to Enso upto 620 million doses of the Sputnik V vaccine and the Sputnik Light vaccine in opposition to Covid-19,” Wockhardt stated in a press release.

The settlement between the Company, HV, Enso was reached below the aegis of Enso, RDIF’s co-ordination accomplice for sourcing Sputnik vaccine in India.

LEAVE A REPLY

Please enter your comment!
Please enter your name here